SRR12696791
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.400
- ADIPOGENESIS+0.300
- INTERFERON_ALPHA_RESPONSE+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- ALLOGRAFT_REJECTION+0.200
- ANDROGEN_RESPONSE+0.200
- COAGULATION+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MTORC1_SIGNALING+0.200
- MYC_TARGETS_V2+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- ANGIOGENESIS-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- KRAS_SIGNALING_DN-0.100
- MYOGENESIS-0.100
- P53_PATHWAY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866853 | — | — | 0.801 |
| 2 | s_150324_8a | EPN | Supratentorial EPN | 0.782 |
| 3 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.781 |
| 4 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.765 |
| 5 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.765 |
| 6 | s_150324_7a | EPN | Supratentorial EPN | 0.753 |
| 7 | 20020064.LumB | — | B | 0.750 |
| 8 | BS_MT15SGJN | EPN | Supratentorial EPN | 0.748 |
| 9 | SRR12696807 | — | — | 0.748 |
| 10 | SRR1797278 | — | cohortSC | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |